Faruqi & Faruqi, LLP is investigating the claims on behalf of Novo Nordisk investor Investing.com

Faruqi & Faruqi, LLP securities litigation partner James (Josh) Wilson He encourages investors who have suffered losses in Novo Nordisk (NYSE: ) to contact him directly to discuss their options

If you bought or acquired securities in Novo Nordisk between November 2, 2022 and December 19, 2024 and want to discuss your legal rights, call a Faruqi & Faruqi partner Josh Wilson direct on 877-247-4292 or 212-983-9330 (ext. 1310).

[You may also click here for additional information]

New York, New York–(Newsfile Corp. – January 26, 2025) – Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Novo Nordisk A/S (“Novo Nordisk” or the “Company ” “) (NYSE: NVO) and reminds investors of The deadline is March 25, 2025 to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The company has recovered hundreds of millions of dollars for investors since its inception in 1995. See www.faruqilaw.com.

As set forth below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose the true status of Novo’s REDEFINE-1 trial protocol; particularly that it was a “flexible protocol” that gave patients the option of “dosage modification during the trial.”

On December 20, 2024, during the pre-market hours, Novo released the main results for its REDEFINE-1 trial, which found that CagriSema achieved an average weight loss of just 22.7% after 68 weeks. The company attributed this reduced score in part to the previously undisclosed “flexible” nature of the protocol. This flexibility resulted in less than 60% of patients apparently completing the dose escalation period and therefore being treated with “2.4 mg cagrilintide and 2.4 mg semaglutide once weekly,” the maximum dose of CagriSem considered in the trial, over the 52-week period. maintenance period in the manner specified in the published protocol for the REDEFINE-1 study.

Investors and analysts immediately reacted to the new discovery. The price of Novo’s ordinary shares fell dramatically. From the closing market price of $103.44 per share on December 19, 2024, Novo’s stock price fell to $85.00 per share on December 20, 2024, a decrease of about 17.83% in the span of just one day .

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class that is adequate and typical of the class members who directs and oversees the litigation on behalf of the putative class. Any putative class member may propose to the Court to serve as lead plaintiff through counsel of his or her choosing, or may choose to do nothing and remain an absent class member. Your ability to participate in any recovery is not affected by the decision whether or not you will be the lead plaintiff.

Faruqi & Faruqi, LLP also encourages anyone with information about Novo Nordisk’s conduct to contact the company, including whistleblowers, former employees, shareholders and others.

Advertising of lawyers. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Past results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your specific case. All communications will be treated confidentially.

To view the original version of this press release, visit https://www.newsfilecorp.com/release/238409